Can a new biologic drug shrink advanced melanoma tumors?

NCT ID NCT06081920

Recruiting now Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This phase II trial is testing an experimental drug called IBI363 in people with advanced melanoma that has worsened after at least one prior treatment. The study aims to see whether IBI363 is safe and can shrink tumors or slow their growth. About 180 participants will receive IBI363 alone, and researchers will track side effects, tumor response, and how long any benefits last.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental biologic drug called IBI363
What this could lead to: If IBI363 proves safe and shrinks tumors, it could offer a new treatment option for advanced melanoma that has stopped responding to standard therapies.
What could go wrong: This is an early phase II trial with only 180 participants, so results may not apply broadly. IBI363 may cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, 350000, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410031, China
Jilin Cancer Hospital
RECRUITING

Changchun, Jilin, 130012, China
Nanjing Drum Tower Hospital
RECRUITING

Nanjing, Jiangsu, 210000, China
Peking University Cancer Hospital & Institute, Beijing, China,
RECRUITING

Beijing, Beijing Municipality, 100142, China
Qilu Hospital of Shandong university
RECRUITING

Jinan, Shandong, 250012, China
Shanxi Bethune Hospital
RECRUITING

Taiyuan, Shanxi, 030032, China
The Third people's hospital of Zhengzhou
RECRUITING

Zhengzhou, Henan, 450044, China
The first affiliated hospital of Nanchang university
RECRUITING

Nanchang, Jiangxi, 330052, China
The first hospital of Jilin University
RECRUITING

Changchun, Jilin, 130021, China
Yunan Cancer Hospital
RECRUITING

Kunming, Yunan, 650118, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.